Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis

Hanan Jafar

Status and phase: Unknown; Phase 1

Conditions: Knee Osteoarthrosis

Treatments: Biological: Wharton Jelly derived mesenchymal stem cell

Study type: Interventional

Funder types: Other

Identifiers

NCT02963727

AlloKneeUJCTC

Details and patient eligibility

About

Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Full description

Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to strict inclusion and exclusion criteria. These patients will be injected with Wharton Jelly derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.

Enrollment: 10 estimated patients

Sex: All

Ages: 42 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Severe KOA stage III or IV by Laurance & Kellgren staging as judged by Posterioranterior (PA) Xray of the knee joint.
• Willing to participate by signing the informed consent

Exclusion criteria

1. Sublaxation beyond 20 degrees of the bones of the knee joint
2. Oral anticoagulants or heparin therapy
3. Heart failure or arrhythmia
4. Body Mass Index > 35
5. Uncontrolled Diabetes Mellitus.
6. Evidence of Infectious Diseases.
7. Active infection
8. Malignancy
9. Pregnancy
10. Anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than 3000.
11. Unreliable patients
12. Non-resident in Jordan

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Wharton Jelly mesenchymal stem cell

Experimental group

Description:

Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose

Treatment:

Biological: Wharton Jelly derived mesenchymal stem cell